-MicroRNAs: New biomarkers for diagnosing HIV-
Authors
Abstract:
According to the increasing number of AIDS patients and their deaths, Treatment is a very important debate to prevent this Which is dependent on early and Accurate diagnosis. Currently, there are different diagnostic methods, including virus cultures, rapid tests, western blot, and other tests for this infection. Among these, HIV RNA TESTING, especially APTIMA HIV RNA ASSAY and fourth generation EIA tests can detect P24 antigens, IgG and IgM antibodies. These tests are highly sensitive and highly recommended, which are approved by the FDA and CDC organizations. In addition, the other new diagnostic method is the using of MicroRNA as a novel diagnostic biomarker for HIV. In this strategy difference between the miRNAs are measured to determine which biomarkers are stable, identifiable, robust, affordable, and are suitable for diagnosis, prognosis and follow-up patients.
similar resources
MicroRNAs as biomarkers associated with bladder cancer
Bladder cancer is the fifth most common cancer with significant morbidity and mortality. Recently, numerous studies demonstrated that microRNAs are emerging as diagnostic biomarkers for bladder cancer. Specific miRNA profiles have been identified for several samples from patients with bladder cancer. MicroRNAs are noncoding RNA molecules of approximately 23 nucleotides that play important roles...
full textMicroRNAs as clinical biomarkers?
A clinical biomarker has been defined as “any cellular, biochemical, molecular, or genetic alterations by which a normal, abnormal, or simple biological process can be recognized or monitored” (Drucker andKrapfenbauer, 2003; Rahim et al., 2015). Biomarkers are widely employed throughout medicine on a day to day basis to diagnose, prognosticate, and predict outcomes of disease and illness or eve...
full textMicroRNAs: new biomarkers and therapeutic targets after cardiac arrest?
Despite advances in resuscitation medicine, including target temperature management as part of post-cardiac arrest care, many patients will have a poor neurological outcome, most often resulting in death. It is a commonly held belief that the ability to prognosticate outcome at an early stage after cardiac arrest would allow subsequent health care delivery to be tailored to individual patients....
full textCirculating microRNAs are new and sensitive biomarkers of myocardial infarction
AIMS Circulating microRNAs (miRNAs) may represent a novel class of biomarkers; therefore, we examined whether acute myocardial infarction (MI) modulates miRNAs plasma levels in humans and mice. METHODS AND RESULTS Healthy donors (n = 17) and patients (n = 33) with acute ST-segment elevation MI (STEMI) were evaluated. In one cohort (n = 25), the first plasma sample was obtained 517 ± 309 min a...
full textCirculating MicroRNAs as Biomarkers for Sepsis
Sepsis represents a major cause of lethality during intensive care unit (ICU) treatment. Pharmacological treatment strategies for sepsis are still limited and mainly based on the early initiation of antibiotic and supportive treatment. In this context, numerous clinical and serum based markers have been evaluated for the diagnosis, the severity, and the etiology of sepsis. However until now, fe...
full textCirculating MicroRNAs: Potential Biomarkers for Cancer
Cancer is the leading cause of death in the world. Development of minimally invasive biomarkers for early detection of cancer is urgently needed to reduce high morbidity and mortality associated with malignancy. MicroRNAs (miRNAs) are small regulatory RNAs that modulate the activity of specific mRNA targets and play important roles in a wide range of physiologic and pathologic processes. Recent...
full textMy Resources
Journal title
volume 11 issue 44
pages 41- 48
publication date 2019-09
By following a journal you will be notified via email when a new issue of this journal is published.
No Keywords
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023